4 ms·
The problem goes deeper than that. "Healthcare industry" is an oxymoron. The incentives of pharmaceutical firms and patients are not aligned, and will not for t
by pygy_ 14y ago
The problem goes deeper than that. "Healthcare industry" is an oxymoron. The incentives of pharmaceutical firms and patients are not aligned, and will not for the foreseeable future (not that I have a better model to offer :-/).
- danpalmer 14y agoOne suggested solution is to remove all patenting on drugs. That way, competition will force prices down, and result in two things. In countries with national healthcare such as the UK, the NHS bill could be drastically reduced, and the government could give grants to drug companies for R&D purposes. In countries with no healthcare system like the US, the general population will have much more money, and so taxes could be increased (hopefully not all the way back up) and grants could be given again. For those who think that drug companies need high prices for recouping R&D costs, their marketing budgets are far greater than R&D budgets, so this isn't really true. In the UK they aren't allowed to market to end-users, so the advertising costs are generally much lower here.
- grandinj 14y agoTheir R&D budgets are still pretty huge. And how exactly do you compete when your competitors can clone your product with ease? And the NHS spends < 10% of drugs, most of which are already available as generics, so there is not a lot of scope for cost reduction. I'm not saying that aren't improvements that can be made, but people need to wake up and realise that there are no simple answers.
- Create 14y agoa substantial part of their R&D budget is "market development"
- wnight 14y agoTheir costs would have been paid for the R&D so it wouldn't be their drug being ripped off, it w would be our drug being second sourced. Also, their costs would be much lower because we'd be paying for the clinical trials and there wouldn't be marketing costs.
- grandinj 14y agoAh, so basically you are saying we should shift the entire cost burden of creating new drugs from the free market to the government. Glad to have that cleared up.
- wnight 14y agoAbsolutely. So glad you understand. It hasn't been a free market since we created the FDA (and I'm not looking to get rid of it), and with patents and advertising law, etc, it's never going to be free. So why don't we change the accounting? Instead of making drugs companies advertise and exploit to be able to pay the regulatory costs, and R&D, etc, why not recognize that they create drugs for us and this is our hurdle - not theirs. We want the product, so we shouldn't dump costs on the drug companies and pretend we've dealt with them. So we should pay for the regulatory testing. 100%. But that leaves an inventive to push expensive and unneeded or dangerous drugs through the system because they don't pay and yet get rewarded. So we need to make these our drugs - by paying for the R&D up front, so that there's no need to game our own system. Now there's no need for secrecy so there's no need for patents to reward letting it go, and everything gets simpler again. When you strip the patents, the marketing, and the legal games, our drugs would get a lot cheaper and more reliable. We'd still be paying for all, maybe even more, tests, but at least we wouldn't have to trust someone whose motive clearly (and reasonably in this system) is to rush to market.
- grandinj 14y agoYes, because government agencies are well known for - cost efficiency - openness to exploring new avenues of research - obeying their own regulatory regimes It'll certainly reduce some gaming of the current system, but I can't see how this will materially improve the situation as a whole.
- DanBC 14y agoYes. Medication compliance (people taking meds correctly) is a severe problem. The UK spends about £9bn on medication, and about half of that is wasted by non-compliance. It's not the severity of the illness; many organ transplants fail because of med non-compliance. It's not the lack of cost of the meds; figures are similar in the US. Getting patients to take meds correctly is a problem waiting for a solution, and there's money to be made from it.
- Create 14y agoAustralia's National Medicines Policy aims to 'meet medication and related needs, so that both optimal health outcomes and economic objectives are achieved for Australians'.3 In response to the rising cost of the Pharmaceutical Benefits Scheme (PBS), the Australian Government has introduced policies to encourage the use of generic drugs. Probably the most significant of these to date have been the Brand Premium Policy (1990) and the Brand Substitution Policy (1994).4 Under the Brand Premium Policy, pharmaceutical manufacturers were allowed to set their own prices for the different brands of the same medicine. The PBS subsidy was determined by the lowest priced brand, the so-called 'benchmark brand'. Patients must pay the difference between the price of the dispensed drug and the benchmark brand. The Brand Substitution Policy allows pharmacists to substitute bioequivalent generic medicines without seeking advice from prescribers, unless otherwise indicated on the prescription. http://www.australianprescriber.com/magazine/27/4/80/1 http://www.australianprescriber.com/magazine/27/4/80/1
- wnight 14y agoThe solution to many problems is eliminating patents, and not just in one area. We, collectively, act as if we're enriching inventors when probably we're hurting them with these laws. If we really cared about rewarding invention we'd pay inventors. But instead all we do is give them a letter of marque and tell them to steal it from others. Those who can, do. Those who can't, pass a law to confiscate it.
- DanBC 14y agoPatents for health are probably okay. But the abuse of the patent system really does need to stop. Companies engaging in illegal, anti-competitive behaviour such as "pay to delay"[1] need to have some realistic punishment applied. [1] (http://www.npr.org/2013/03/25/175043758/supreme-court-hears-pay-to-delay-pharmaceutical-case?ft=1&f=1014 http://www.npr.org/2013/03/25/175043758/supreme-court-hears-...)